Effect of hyaluronidase and PEG chain conjugation on the biologic and antitumor activity of RNase A
Introduction
Various biological aspects of bovine pancreatic ribonuclease (RNase A) has been intensively studied for many years [7], [29]. Some antitumor effect of this enzyme was found shortly after its isolation [19]. However, the inhibition of its antitumor and other biological activities by ribonuclease inhibitor (RI) in cytosol was the main reason for the low cytotoxic activity of this RNase. From this reason, an attention of scientists in the last years was focussed on the mutation of recombinant RNase A, human pancreatic RNase (HPRNase), and on efforts to block the binding of RI to this molecule. Beside producing a simple mutation in the synthetic gene of RNase A [20] the conjugation of this monomeric ribonuclease with transferrin, poly [N-(2 hydroxypropyl) methacrylamide] or polyethylen glycol (PEG) seems to help to solve this relevant problem [25], [32], [36], [38].
The effects of bovine even ovine testicle hyaluronidase (HYase), a matrix-degrading enzyme, were studied in the last years in extracts from various primary tumors and regional metastases [2]. They were also used as additives to induction chemotherapy and enhancement of the permeation of chemotherapeutics into tumor tissue with a matrix rich on hayluronic acid [1], [17], [18], [28] or hyaluronan synthase [12]. The further positive effect of HYase to tumors has been directed to use this enzyme as chemosensitizer, which acts as antiadhesive agent rendering solid resistant tumors more susceptible to conventional therapeutic drugs [34]. Notably, hyaluronidase increases tumor necrosis factor (TNF) sensitivity in several types of cancer cells, counteracts transforming growth factor beta (TGF-beta), mediated TNF-resistance and suppresses TGF-beta 1 gene expression in L 929 cells which are enable to resist TNF killing [5]. The possibility to modulate the expression of CD 44 (transmembrane glycoproteins) expressed on a wide variety of cells, including cancer cells, by HYase seems to be also positive for the prevention of tumor growth [13], [30], [35], [40], [30], [13].
It is also demonstrated that the membrane-associated HYase can act in vivo, and that hyaluronan, which is synthesized by the tumor stroma, can be made soluble and reduced to a smaller size by tumor cells before being internalized and further digested [8]. HYase is well tolerated by the test animals [33]. In a prospective pilot study, patients with advanced inoperable squamous cell carcinoma of the head and neck were treated with polychemotherapy and hyaluronidase combined with radiation therapy. The published results suggested that combined therapy with vindesine, cisplatin, HYase, and radiation were highly effective against this squamous cell cancer [17].
Even though some negative experiments showed that elevated HYase levels correlate with tumor metastasis and angiogenesis [9], [21], [22], [23], [39] we conjugated bovine HYase to RNase A. Beside this conjugate we joined to the RNase+HYase complex the PEG chain polymer yet. These two RNase polymerized conjugates were studied biologically.
Section snippets
Chemicals
Bovine pancreatic ribonuclease—RNase A (aggregate)—free beef pancreas, activity 75 Kunitz U/mg was purchased from ICN Biomedicals Inc. USA. Activated derivative of polyethylene glycol (PEG), MW 5129 was obtained from Sherwater Polymers, Inc. USA. The supplier of hyaluronidase produced from ovine testes, activity: 2502 U/mg was again ICN Biomedicals. All other reagents and solvents were of analytical grade.
RNase A+hyaluronidase intermolecular conjugate
The preparation was performed using heterobifunctional reagent SPDP (N-succinimidyl 3-/2-
Effects of free RNase A and its conjugates with HYase and PEG polymers on mice spermatogenesis
The aspermatogenic effects of the preparations obtained following subcutaneous application to the mice are given in Table 1. The free RNase A injected by the dose of 100 μg once a week for 5 weeks did not influence the weight of mouse testes nor the width of spermatogenic layers or the seminiferous tubules diameter.
In contrast to subcutaneous application of free RNase A, this enzyme when conjugated to HYase, PEG and HYase+PEG resulted in a marked reduction of the width of the spermatogenic
Discussion
Bovine pancreatic ribonuclease (RNase A) is an enzyme, which has been studied in detail on the basis of its structural and functional properties since 1955 when Ledoux [19] reported its anticancer properties on mice bearing two experimental tumors. Later on, a cytotoxic RNase (BS-RNase), isolated from bovine seminal plasma [6] or seminal vesicle fluid [10], was found to be an 80% homolog to RNase A in sequence and was reported to exert specific biological properties such as aspermatogenic,
Acknowledgements
This work was supported by a grant from the Grant Agency of the Czech Republic (No. 523/01/0114). We wish to express our thanks to Miluše Hokešová for the technical assistance she provided in this study and to Dr. Tomas Slavik for the embryotoxicity testing.
References (40)
- et al.
The impact of extracellular matrix on the chemoresistence of solid tumors—experimental and clinical results of hyaluronidase as additive to cytostatic chemotherapy
Cancer Lett.
(1998) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein—dye binding
Anal. Biochem.
(1976)- et al.
Dimeric structure of seminal ribonuclease
FEBS Lett.
(1972) - et al.
Mechanism of ribonuclease cytotoxicity
J. Biol. Chem.
(1995) - et al.
Conformational stability is a determinant of ribonuclease A cytotoxicity
J. Biol. Chem.
(2000) - et al.
Plasma hyaluronidase (Hyal-1) promotes tumor cell cycling
Cancer Lett.
(2001) - et al.
PEG chains increase aspermatogenic and antitumour activity of RNase A and BS-RNase enzymes
J. Control. Release
(2002) - et al.
Hyaluronidase additional to standard chemotherapy improves outsome for children with malignant brain tumors
Cancer Lett.
(1998) - et al.
Immunosuppressive activity of bovine seminal ribonuclease and its mode of action
Immunobiology
(1996) - et al.
Reversal of intrinsic and acquired forms of drug resistance by hyaluronidase treatment of solid tumors
Cancer Lett.
(1998)